Back to discover
Disease
Heart Failure, Systolic
Late-stage therapeutic developmentEmerging research
2
Publications
24
Clinical trials
1
Related conditions
12
Associated genes
1
Related proteins
2021
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Clinical trial2026-08-06Status changed to Completed · ClinicalTrials.gov
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 6 clinical trials expected to report results, the earliest in Q4 2027.
Upcoming Milestones
- Q4 2027Evaluation of Digoxin Therapy in Patients With Heart Failure After Acute Decompensation
- Q4 2027GOREISAN for Heart Failure (GOREISAN-HF) Trial
- Q2 2028A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction
- Q3 2029Efficacy and Safety of NNC0487-0111 Compared to Placebo on Morbidity and Mortality in People With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Q4 2030A Phase 3, Single-arm, Open-label Extension Study to Evaluate the Safety of Finerenone in Addition to Standard of Care, in Pediatric Heart Failure Patients, From Birth to 18 Years of Age, With Left Ventricular Systolic Dysfunction (LVSD)
Major developments
Upcoming trial readoutHigh impact
Results expected Q2 20282026-08-19
Upcoming trial readoutHigh impact
Results expected Q3 20292026-08-18
Clinical MilestonesView all 16Hide
Results expected
- 2026-08-19A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection FractionResults expected Q2 2028
- 2026-08-18Efficacy and Safety of NNC0487-0111 Compared to Placebo on Morbidity and Mortality in People With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityResults expected Q3 2029
- 2026-06-29A Phase 3, Single-arm, Open-label Extension Study to Evaluate the Safety of Finerenone in Addition to Standard of Care, in Pediatric Heart Failure Patients, From Birth to 18 Years of Age, With Left Ventricular Systolic Dysfunction (LVSD)Results expected Q4 2030
- 2026-06-02Evaluation of Digoxin Therapy in Patients With Heart Failure After Acute DecompensationResults expected Q4 2027
- 2026-05-19A Registry-Based Randomised Controlled Trial With Heart 4 Data - SELEnium and CoQ10 NuTrition for Heart Failure: H4D-SELEQT-HFResults expected Q4 2030
Recently completed
- 2026-06-25A Double-blind,Randomized, Placebo-controlled Study to Assess Exercise Tolerance After Iron Repletion With Ferric Derisomaltose (Monoferric®) IV Compared to Placebo in Heart Failure With Preserved Ejection Fraction and With Iron Deficiency.Completed
- 2026-06-17A Multi-Ethnic, Multi-centre raNdomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction (AMEND-preserved)Completed
- 2026-05-31The Effect of Dapagliflozin on Patients With CardiomyopathyCompleted
- 2026-05-10The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEFCompleted
- 2026-05-09Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve RegurgitationCompleted
Other updates
- 2026-11-27Omecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HFWithdrawn
- 2026-09-03Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic InflammationTerminated
- 2026-03-31IRONICA: IRON Repletion in Congestive Heart Failure - A Randomized Controlled Trial Comparing Oral Versus IV ApproachesTerminated
- 2026-01-21Acute Hemodynamic and Blood Volume Effects of Single-Dose Intranasal Bumetanide in Patients Implanted With the CardioMEMS™ and Cordella™ HF Systems: a 24-Hour Prospective Pilot StudyWithdrawn
+8 more in the activity timeline below
Activity timeline16
- 2026-11-27ClinicalOmecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HFWithdrawn
- 2026-09-03ClinicalEffects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic InflammationTerminated
- 2026-08-19ClinicalA Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection FractionResults expected Q2 2028
- 2026-08-18ClinicalEfficacy and Safety of NNC0487-0111 Compared to Placebo on Morbidity and Mortality in People With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityResults expected Q3 2029
- 2026-06-29ClinicalA Phase 3, Single-arm, Open-label Extension Study to Evaluate the Safety of Finerenone in Addition to Standard of Care, in Pediatric Heart Failure Patients, From Birth to 18 Years of Age, With Left Ventricular Systolic Dysfunction (LVSD)Results expected Q4 2030
- 2026-06-25ClinicalA Double-blind,Randomized, Placebo-controlled Study to Assess Exercise Tolerance After Iron Repletion With Ferric Derisomaltose (Monoferric®) IV Compared to Placebo in Heart Failure With Preserved Ejection Fraction and With Iron Deficiency.Completed
- 2026-06-17ClinicalA Multi-Ethnic, Multi-centre raNdomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction (AMEND-preserved)Completed
- 2026-06-02ClinicalEvaluation of Digoxin Therapy in Patients With Heart Failure After Acute DecompensationResults expected Q4 2027
- 2026-05-31ClinicalThe Effect of Dapagliflozin on Patients With CardiomyopathyCompleted
- 2026-05-19ClinicalA Registry-Based Randomised Controlled Trial With Heart 4 Data - SELEnium and CoQ10 NuTrition for Heart Failure: H4D-SELEQT-HFResults expected Q4 2030
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approved & established therapies
Ivabradine hydrochlorideapproved
Generic approval — Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the s… (2017)
Ivabradineapproved
Original application approval — Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the s… (2015)
Dronedaroneapproved
Original application approval — Multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in… (2009)
Clinical trials
The current development programme across all trial phases.
Clinical programme
24
6
18
6
Late-stage studies
Recruiting
Recently completed
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
Product approvals and authorisations
2017emaGeneric approval — Ivabradine hydrochloride· Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated : - in adults unable to tolerate or with a contra-indication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. (see section 5.1) source ↗
2016emaGeneric approval — Ivabradine hydrochloride· Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated: in adults unable to tolerate or with a contra-indication to the use of beta-blockers or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. source ↗
2015emaOriginal application approval — Ivabradine· Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated: in adults unable to tolerate or with a contra-indication to the use of beta-blockers or in combination with beta-blockers in patients inadequately controlled with an optimal betablocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. source ↗
2009emaOriginal application approval — Dronedarone· Multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF). Due to its safety profile, Multaq should only be prescribed after alternative treatment options have been considered. Multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure. source ↗
2005emaOriginal application approval — Ivabradine hydrochloride· Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated: in adults unable to tolerate or with a contraindication to the use of beta-blockers or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. source ↗
2005emaOriginal application approval — Ivabradine hydrochloride· Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated : in adults unable to tolerate or with a contraindication to the use of beta-blockers or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. source ↗
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
Most influential
Major themes2
- Cardiac Pacing, Artificial1
- Defibrillators, Implantable1
Leading journals1
- The New England journal of medicine2
Leading researchers8
- Abbasi SA1
- Adams KF1
- Anand I1
- Arias-Mendoza A1
- Biering-Sørensen T1
- Böhm M1
- Bonderman D1
- Brandes A1
Affiliations (unnormalised)2
- Rigshospitalet (L.K.1
- San Francisco Veterans Affairs Medical Center and School of Medicine1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Heart failure caused by abnormal myocardial contraction during SYSTOLE leading to defective cardiac emptying.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.